Navigation Links
Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences

Caliper Life Sciences, Inc. (Nasdaq: CALP) and Affymetrix, Inc. (Nasdaq: AFFX) today announced that Caliper has issued Affymetrix a non-exclusive license to use a portion of Caliper's microfluidics patent estate with Affymetrix' GeneChip(R) microarray technologies. The license extends to the manufacture and sale of GeneChip brand products in all areas of application, including research, diagnostics and applied genomics applications. In exchange for the license, Affymetrix will pay upfront licensing fees and royalties on future products covered under the agreement. Further financial details related to the agreement were not disclosed.

The agreement announced today is the second agreement since Caliper began an active program to out-license its intellectual property portfolio. The new "LabChip Driven" program was put in place to support the company's microfluidics adoption strategy and to broaden and accelerate the availability of new technologies and products for life science and diagnostics applications.

"The potential for merging two technologies on the forefront of life science innovation represents an important option for us," said Alan Sherr, Director of Licensing for Affymetrix. "We have worked successfully with Caliper as a partner for a year now, and are pleased to be able to extend the scope of our relationship with Caliper to this new area of potential value and importance to Affymetrix' customers."

"We are pleased that a leading life sciences company like Affymetrix recognizes the vast potential of LabChip technologies," said Kevin Hrusovsky, President and CEO at Caliper. "Affymetrix is moving beyond basic research applications and is pioneering areas such as pharmacogenomics and personalized medicine. Incorporating our technologies -- first laboratory automation and now the potential for Caliper's microfluidics technologies -- into these vital areas of human health is important to our corporate ideals and to our future as a key tech nology provider to the industry."

The scope of the license agreement includes nucleic acids processing and handling associated with GeneChip arrays, but excludes the right to use LabChip technology with respect to products intended primarily to perform nucleic acid separations as a discrete, non-integrated quality control step.


'"/>

Source:Affymetrix


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
6. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
7. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
8. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
9. Affymetrix 500K array used to identify memory gene
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. Technology for monitoring fetal oxygen during labor offers no apparent benefit
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and ... entered into an agreement to develop a cloud ... By providing a holistic view of the multiple ... Watson Cognitive Insights could be designed to support ... Health is an innovative nonprofit healthcare organization with ...
(Date:2/18/2017)... Feb 17, 2017 Research and Markets has ... Report" report to their offering. ... The report provides separate comprehensive analytics for ... , and Rest of World. Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
Breaking Biology Technology: